Acoramidis · Attruby
Small molecule
Evidence outlook
Approved: Transthyretin Amyloidosis with Cardiomyopathy
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Also approved (2)
- for the treatment of adults with ATTR-CM in Japan
- For the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
ATTRibute-CM NCT03860935 · Transthyretin Amyloidosis with Cardiomyopathy Registry: NCT03860935 | 3 | A Hierarchical Combination of All-Cause Mortality, Cumulative Frequency of CV-related Hospitalization, Change From Baseline in NT-proBNP and Change From Baseline in 6MWT at the Last Available Visit Where Both Subjects Had Non-missing Assessments. (Baseline up to Month 30) 2023-05-11 | A Hierarchical Combination of All-Cause Mortality, Cumulative Frequency of CV-related Hospitalization, Change From Baseline in NT-proBNP and Change From Baseline in 6MWT at the Last Available Visit Where Both Subjects Had Non-missing Assessments. (Baseline up to Month 30): Acoramidis HCl 800 mg 63.7 Percent of Wins from Win Ratio | Placebo 35.9 Percent of Wins from Win Ratio | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Phase 4 (3)
What this study did
What this study did
What this study did
Competitive landscape
Other Transthyretin (TTR) drugs
Eplontersen, Patisiran, Vutrisiran, Inotersen, Cliramitug and 3 more. Compare all 9 Transthyretin (TTR) drugs
This mechanism is crowded: 8 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Transthyretin Amyloidosis with Cardiomyopathy: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Acoramidis (Attruby): this drug | Approved | Small molecule | Transthyretin (TTR) | not yet graded | No reviewed efficacy summary in this indication | |
| Patisiran (ONPATTRO) | Approved(overall) | RNA / oligonucleotide | Transthyretin (TTR) | Reliable signal(overall) | NCT03997383: Change From Baseline at Month 12 in Six-Minute Walk Test (6-MWT) (Baseline, Month 12): Placebo (DB)/Patisiran (OLE) -21.345 meters (95% CI -68.268 to 12.75) | Patisiran (DB+OLE) -8.15 meters (95% CI -54.651 to 29.51) | |
| Vutrisiran (AMVUTTRA) | Approved | RNA / oligonucleotide | Transthyretin (TTR) | Reliable signal | NCT04153149: Composite of all-cause mortality and recurrent cardiovascular events: overall population HR 0.718 (95% CI 0.555 to 0.929), p=0.0118; vutrisiran monotherapy subgroup HR 0.672 (95% CI 0.487 to 0.929), p=0.0162 | |
| Inotersen (Tegsedi) | US approval withdrawn(overall) | RNA / oligonucleotide | Transthyretin (TTR) | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Cliramitug | Phase 3 | Monoclonal antibody | Transthyretin (TTR) | not yet graded | No reviewed efficacy summary in this indication | |
| Coramitug | Phase 3(overall) | Monoclonal antibody | Transthyretin (TTR) | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Eplontersen (Wainua) | Phase 3 | RNA / oligonucleotide | Transthyretin (TTR) | Partial signal | NCT04136171: CARDIO-TTRansform primary composite: rate ratio 0.89 (95% CI 0.73 to 1.09), P=0.28; no significant reduction. missed | |
| Nexiguran Ziclumeran | Phase 3 | Gene therapy / editing | Transthyretin (TTR) | not yet graded | No reviewed efficacy summary in this indication | |
| Nucresiran | Phase 3 | RNA / oligonucleotide | Transthyretin (TTR) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(6 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Attruby (Acoramidis) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.